These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 12792155)

  • 41. Functional group interactions of a 5-HT3R antagonist.
    Venkataraman P; Joshi P; Venkatachalan SP; Muthalagi M; Parihar HS; Kirschbaum KS; Schulte MK
    BMC Biochem; 2002 Jun; 3():16. PubMed ID: 12079499
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The impact of arteriovenous concentration differences on pharmacodynamic parameter estimates.
    Tuk B; Danhof M; Mandema JW
    J Pharmacokinet Biopharm; 1997 Feb; 25(1):39-62. PubMed ID: 9353693
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Symposium on geriatrics--Part I: Drug prescribing for elderly patients.
    Chutka DS; Evans JM; Fleming KC; Mikkelson KG
    Mayo Clin Proc; 1995 Jul; 70(7):685-93. PubMed ID: 7791396
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Streptozotocin-Induced Hyperglycemia Affects the Pharmacokinetics of Koumine and its Anti-Allodynic Action in a Rat Model of Diabetic Neuropathic Pain.
    Ye LX; Huang HH; Zhang SH; Lu JS; Cao DX; Wu DD; Chi PW; Hong LH; Wu MX; Xu Y; Yu CX
    Front Pharmacol; 2021; 12():640318. PubMed ID: 34054521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Applying linear and non-linear methods for parallel prediction of volume of distribution and fraction of unbound drug.
    del Amo EM; Ghemtio L; Xhaard H; Yliperttula M; Urtti A; Kidron H
    PLoS One; 2013; 8(10):e74758. PubMed ID: 24116008
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population pharmacodynamic parameter estimation from sparse sampling: effect of sigmoidicity on parameter estimates.
    Pai SM; Girgis S; Batra VK; Girgis IG
    AAPS J; 2009 Sep; 11(3):535-40. PubMed ID: 19629711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Practical uses of individual pharmacokinetic parameters in drug development and clinical practice: examples and simulations.
    Bjornsson TD
    Eur J Drug Metab Pharmacokinet; 1997; 22(1):1-14. PubMed ID: 9179555
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pharmacokinetics of 6-mercaptopurine in rats during postnatal development].
    Wierzba K; Wańkowicz B; Piekarczyk A; Prokopczyk J
    Probl Med Wieku Rozwoj; 1984; 13():207-12. PubMed ID: 6543392
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.
    Mangoni AA; Jackson SH
    Br J Clin Pharmacol; 2004 Jan; 57(1):6-14. PubMed ID: 14678335
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose-dependent uptake, distribution, and elimination of inhaled n-hexane in the Fischer-344 rat.
    Baker TS; Rickert DE
    Toxicol Appl Pharmacol; 1981 Dec; 61(3):414-22. PubMed ID: 7330882
    [No Abstract]   [Full Text] [Related]  

  • 51. Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model.
    Abduljalil K; Jamei M; Rostami-Hodjegan A; Johnson TN
    AAPS J; 2014 May; 16(3):568-76. PubMed ID: 24700271
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and pharmacological effect of lerisetron, a new 5-HT3 antagonist, in rats.
    Jauregizar N; Calvo R; Suarez E; Quintana A; Raczka E; Lukas JC
    J Pharm Sci; 2002 Jan; 91(1):41-52. PubMed ID: 11782896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic-pharmacodynamic modeling of the hydroxy lerisetron metabolite L6-OH in rats: an integrated parent-metabolite model.
    Ortega F; Quintana A; Suárez E; Lukas JC; Jauregizar N; de la Fuente L; Lucero ML; Gonzalo A; Orjales A; Calvo R
    Pharm Res; 2005 Nov; 22(11):1769-82. PubMed ID: 16158214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug therapy in the elderly.
    Williams L; Lowenthal DT
    South Med J; 1992 Feb; 85(2):127-31. PubMed ID: 1738877
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Age-related changes in pharmacokinetics and pharmacodynamics of lerisetron in the rat: a population pharmacokinetic model.
    Jauregizar N; Quintana A; Suarez E; Raczka E; de la Fuente L; Calvo R
    Gerontology; 2003; 49(4):205-14. PubMed ID: 12792155
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Altered disposition and effect of lerisetron in rats with elevated alpha 1-acid glycoprotein levels.
    Jauregizar N; Calvo R; Suarez E; Quintana A; Raczka E; Lukas JC
    Pharm Res; 2001 Jun; 18(6):838-45. PubMed ID: 11474789
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.